Newsroom

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference

Jul 30, 2014 3:06:29 PM

Data addresses key issues associated with effective translation, translocation and secretion of therapeutic proteins in mammalian cell lines

Selexis SA to Present New Data and a Case Study at
IBC’s Cell Line Development and Engineering Conference

Data addresses key issues associated with effective translation, translocation and secretion of therapeutic proteins in mammalian cell lines

Geneva, Switzerland July 30, 2013 – Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, announced today new data from the Company’s SURE CHO-Mplus Libraries™ will be presented at the 10th Annual Cell Line Development and Engineering conference being held, September 8 – 10, 2014 at the Double Tree by Hilton Berkeley Marina in Berkeley, California.

The following abstract will be presented during an oral presentation:

Title: Genome Engineering Using Larger or Multiple Inserts

Presenter: Pierre-Alain Girod, PhD, Chief Science Officer

Session Date/Time: Monday, September 8, 2014 at 9:45 AM
Session Detail: Progress in Host Cell Engineering tract

Utilizing the data from the completed CHO-M Genome and Transcriptome project, we identified areas in the CHO-M secretory pathway where key secretory pathways proteins levels were either missing or expressed at inappropriate levels. We concurrently developed a vector system that allowed us to engineer the CHO-M secretory pathway by inserting multiple genes into the genome simultaneously. Using this technology, we generated a panel of CHO-based libraries consisting of multiple genes addressing key issues associated with effective translation, translocation and secretion. A case study evaluating co-expression of multiple chaperones simultaneously on recombinant protein production levels will be presented.

Featured